Isaac Israel - Purple Biotech CEO Director

KTOV Stock  ILA 7.40  0.60  7.50%   

Insider

Isaac Israel is CEO Director of Purple Biotech
Age 45
Phone972 3 933 3121
Webhttp://www.kitovpharma.com

Purple Biotech Management Efficiency

The company has return on total asset (ROA) of (0.0915) % which means that it has lost $0.0915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9204) %, meaning that it generated substantial loss on money invested by shareholders. Purple Biotech's management efficiency ratios could be used to measure how well Purple Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Purple Biotech has accumulated 117 K in total debt with debt to equity ratio (D/E) of 0.0, which may suggest the company is not taking enough advantage from borrowing. Purple Biotech has a current ratio of 2.18, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Purple Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Purple Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Purple Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Purple to invest in growth at high rates of return. When we think about Purple Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Eli AmonICL Israel Chemicals
54
Annat KatzPhotomyne
N/A
Amit HaiotZanlakol
63
Yaackov NadbornyB Communications
58
Ilan ChaikinB Communications
69
Noam GoldsteinICL Israel Chemicals
62
Ofir HuberPhotomyne
N/A
Elad AharonsonICL Israel Chemicals
49
Ilan SigalBezeq Israeli Telecommunication
48
Yair SegalovitzPhotomyne
48
Etty KligerClal Biotechnology Industries
N/A
Shmuel GalmidiZanlakol
N/A
Eran NirKamada
50
Liron KutziPhotomyne
N/A
Ari ShamissKamada
N/A
Advocate GevaHarelICL Israel Chemicals
46
Amir MeshulamICL Israel Chemicals
43
Natalie VerterPhotomyne
43
Liat NissanClal Biotechnology Industries
N/A
Nitzan MosheICL Israel Chemicals
52
Nir TzemahPhotomyne
48
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people. Purple Biotech (KTOV) is traded on Tel Aviv Stock Exchange in Israel and employs 9 people.

Management Performance

Purple Biotech Leadership Team

Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Itzhak Israel, Chief Executive Officer & Director
Steven Steinberg, Independent Director
Gil BenMenachem, Vice President - Business Development
Michael Schickler, Head of Clinical Operations
CPA MBA, Strategic Director
Arie Weber, Independent Director
Bertrand Liang, Chief Medical Officer
Yisrael Gewirtz, Internal Auditor
Ran Tzror, Independent Director
Gil Efron, Deputy Chief Executive Officer, Chief Financial Officer
Simcha Rock, CFO, Director
Eric Rowinsky, Chairman of the Board
Ido Agmon, Independent Director
Gil CPA, Deputy CFO
Isaac Israel, CEO Director
Revital SternRaff, Independent Director
Avraham BenTzvi, General Counsel, Secretary
Hadas Reuveni, Founder and Chief Technology Officer of TyrNovo (a subsidiary)

Purple Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Purple Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Purple Stock

When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.
You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.